|
1
|
Singh D, Upadhyay G, Srivastava RK and
Shankar S: Recent advances in pancreatic cancer: Biology,
treatment, and prevention. Biochim Biophys Acta. 1856:13–27.
2015.PubMed/NCBI
|
|
2
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Erkan M, Kleeff J, Esposito I, Giese T,
Ketterer K, Büchler MW, Giese NA and Friess H: Loss of BNIP3
expression is a late event in pancreatic cancer contributing to
chemoresistance and worsened prognosis. Oncogene. 24:4421–4432.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Akada M, Crnogorac-Jurcevic T, Lattimore
S, Mahon P, Lopes R, Sunamura M, Matsuno S and Lemoine NR:
Intrinsic chemore-sistance to gemcitabine is associated with
decreased expression of BNIP3 in pancreatic cancer. Clin Cancer
Res. 11:3094–3101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Manu KA, Chai TF, Teh JT, Zhu WL, Casey PJ
and Wang M: Inhibition of isoprenylcysteine
carboxylmethyltransferase induces cell-cycle arrest and apoptosis
through p21 and p21-regulated BNIP3 induction in pancreatic cancer.
Mol Cancer Ther. 16:914–923. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bujak AL, Crane JD, Lally JS, Ford RJ,
Kang SJ, Rebalka IA, Green AE, Kemp BE, Hawke TJ, Schertzer JD and
Steinberg GR: AMPK activation of muscle autophagy prevents
fasting-induced hypoglycemia and myopathy during aging. Cell Metab.
21:883–890. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang FT, Peng JF, Cheng WJ, Zhuang YY,
Wang LY, Li CQ, Tang J, Chen WY, Li YH and Zhang SN: MiR-143
targeting TAK1 attenuates pancreatic ductal adenocarcinoma
progression via MAPK and NF-κB pathway in vitro. Dig Dis Sci.
62:944–957. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mørk S, Pletscher-Frankild S, Palleja Caro
A, Gorodkin J and Jensen LJ: Protein-driven inference of
miRNA-disease associations. Bioinformatics. 30:392–397. 2014.
View Article : Google Scholar
|
|
9
|
Tang W, Zhu J, Su S, Wu W, Liu Q, Su F and
Yu F: MiR-27 as a prognostic marker for breast cancer progression
and patient survival. PLoS One. 7:e517022012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma J, Fang B, Zeng F, Pang H, Ma C and Xia
J: Grape seed proanthocyanidins extract inhibits pancreatic cancer
cell growth through down-regulation of miR-27a expression. Zhong
Nan Da Xue Xue Bao Yi Xue Ban. 40:46–52. 2015.In Chinese.
PubMed/NCBI
|
|
11
|
Wang WS, Liu LX, Li GP, Chen Y, Li CY, Jin
DY and Wang XL: Combined serum CA19-9 and miR-27a-3p in peripheral
blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev
Res (Phila). 6:331–338. 2013. View Article : Google Scholar
|
|
12
|
Huang R, Wang X, Zhang W, Zhangyuan G, Jin
K, Yu W, Xie Y, Xu X, Wang H and Sun B: Down-regulation of LncRNA
DGCR5 correlates with poor prognosis in hepatocellular carcinoma.
Cell Physiol Biochem. 40:707–715. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen EG, Zhang JS, Xu S, Zhu XJ and Hu HH:
Long non-coding RNA DGCR5 is involved in the regulation of
proliferation, migration and invasion of lung cancer by targeting
miR-1180. Am J Cancer Res. 7:1463–1475. 2017.PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Ye Y, Chen J, Zhou Y, Fu Z, Zhou Q, Wang
Y, Gao W, Zheng S, Zhao X, Chen T and Chen R: High expression of
AFAP1-AS1 is associated with poor survival and short-term
recurrence in pancreatic ductal adenocarcinoma. J Transl Med.
13:1372015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohammed S, Van Buren G II and Fisher WE:
Pancreatic cancer: Advances in treatment. World J Gastroenterol.
20:9354–9360. 2014.PubMed/NCBI
|
|
17
|
Li X, Wu Z, Fu X and Han W: lncRNAs:
Insights into their function and mechanics in underlying disorders.
Mutat Res Rev Mutat Res. 762:1–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer-A brief overview. Adv Biol Regul. 57:1–9.
2015. View Article : Google Scholar
|
|
19
|
Xu L, Xiang J, Shen J, Zou X, Zhai S, Yin
Y, Li P, Wang X and Sun Q: Oncogenic MicroRNA-27a is a target for
genistein in ovarian cancer cells. Anticancer Agents Med Chem.
13:1126–1132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma Y, Yu S, Zhao W, Lu Z and Chen J:
miR-27a regulates the growth, colony formation and migration of
pancreatic cancer cells by targeting Sprouty2. Cancer Lett.
298:150–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu W, Liu M, Peng X, Zhou P, Zhou J, Xu K,
Xu H and Jiang S: miR-24-3p and miR-27a-3p promote cell
proliferation in glioma cells via cooperative regulation of MXI1.
Int J Oncol. 42:757–766. 2013. View Article : Google Scholar
|
|
22
|
Wu XZ, Wang KP, Song HJ, Xia JH, Jiang Y
and Wang YL: MiR-27a-3p promotes esophageal cancer cell
proliferation via F-box and WD repeat domain-containing 7 (FBXW7)
suppression. Int J Clin Exp Med. 8:15556–15562. 2015.PubMed/NCBI
|
|
23
|
Zhou L, Liang X, Zhang L, Yang L, Nagao N,
Wu H, Liu C, Lin S, Cai G and Liu J: MiR-27a-3p functions as an
oncogene in gastric cancer by targeting BTG2. Oncotarget.
7:51943–51954. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mahon PC, Baril P, Bhakta V, Chelala C,
Caulee K, Harada T and Lemoine NR: S100A4 contributes to the
suppression of BNIP3 expression, chemoresistance, and inhibition of
apoptosis in pancreatic cancer. Cancer Res. 67:6786–6795. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee H and Paik SG: Regulation of BNIP3 in
normal and cancer cells. Mol Cells. 21:1–6. 2006.PubMed/NCBI
|
|
26
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and
Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation,
differentiation, migration, senescence and apoptosis. J Recept
Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
